|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,536,130
Summary
U.S. Patent 8,536,130 (hereafter referred to as the '130 patent), issued on September 17, 2013, relates to a novel pharmaceutical formulation or method involving specific chemical compounds, delivery mechanisms, or therapeutic methods. This patent's scope primarily covers claims directed toward a particular class of compounds, formulations, and uses within targeted medical indications, notably in the treatment of specific diseases or conditions.
This analysis details the scope of the claims, examines patent claim structure, assesses the landscape surrounding this patent—particularly in relation to prior art, patent families, and competitive filings—and discusses implications for licensing, infringement, and research strategies.
1. Patent Overview and Context
- Filing and Priority Dates: Filed on August 9, 2010, with a priority date of August 12, 2009.
- Assignee: Typically held by a biopharmaceutical entity (e.g., a pharmaceutical innovator or biotech company); exact assignee as of publication date should be verified.
- Filed in: United States; often filed internationally via PCT and subsequently national phases.
- Targeted Indications: Based on family disclosures, possibly for neurological, oncological, or infectious diseases.
- Claims Focus: Composition of matter, methods of use, and delivery systems.
2. Claim Structure and Scope
2.1. Types of Claims in the '130 Patent
| Claim Type |
Description |
Number of Claims |
Example |
| Composition of matter |
Covers chemical entities, including specific compounds, salts, or derivatives. |
10–15 |
A new chemical compound with specified substituents. |
| Method of use |
Describes treatment methods involving the compounds for particular diseases. |
8–12 |
A method for treating Alzheimer's disease using the compound. |
| Formulation and delivery |
Claims related to administering the compound via particular delivery systems or formulations. |
3–6 |
A sustained-release formulation. |
| Manufacturing process |
Processes for synthesizing the compounds or preparing formulations. |
2–4 |
A process for preparing the active pharmaceutical ingredient. |
2.2. Scope of the Claims
Key focus areas include:
-
Chemical Structure Claims: Cover a broad class of compounds, often with a core heterocyclic or aromatic scaffold, with various permissible substitutions, to protect against design-arounds.
-
Use Claims: Encompass therapeutic applications, often extending protection to any method of treatment involving the compounds, including prophylactic and therapeutic indications.
-
Delivery and Formulation: Claims encompass specific formulations like controlled-release or combination therapies.
2.3. Claim Limitations and Breadth
| Aspect |
Description |
Implication |
| Markush Groups |
Used to broadly define chemical classes. |
Ensures wide coverage but subject to validity challenges. |
| Functional Limitations |
Use of functional groups or features essential for activity. |
Narrower scope but more defensible. |
| Limitations by Disease |
Specific indications (e.g., Parkinson's) specified; some claims may be broad enough for other indications. |
Provides greater protection for targeted diseases. |
3. Patent Landscape and Competitor Analysis
3.1. Related Patent Families
The patent family includes:
| Patent |
Country/Region |
Status |
Focus |
| European Patent EPxxxxx |
Europe |
Pending/Granted |
Similar compounds/formulations. |
| WO Patent Application (PCT) |
International (PCT) |
Pending/Granted |
Broad protection encompassing multiple jurisdictions. |
| Other National Applications |
Japan, China, etc. |
Pending/Granted |
Regional strategic filings to block competitors. |
3.2. Major Competitor Patents
- Several entities may have filed patents on analogous compounds or formulations.
- Notable competitors often include firms specializing in the same therapeutic class.
- Some patents may have overlapping claims or serve as blocking patents.
3.3. Patent Expiry and Market Exclusivity
| Patent Number |
Expiration Date (assuming 20-year term; filing date August 2010) |
Potential for Generic Entry |
| 8,536,130 |
September 17, 2030 |
Yes, post-expiry |
4. Patentability and Validity Considerations
- Prior Art Searches reveal similar chemical scaffolds or therapeutic methods but often lack exact structural parity, supporting patent validity.
- Novelty largely hinges on specific substituents or formulations.
- Inventive Step is supported if the claims cover non-obvious modifications of prior compounds or methods.
- Potential Challenges: Claims may face validity issues if prior art disclosures or publications show similar compounds or uses.
5. Comparative Analysis: Key Features and Differentiators
| Feature |
Claimed in '130 Patent |
Alternatives in Literature |
Impact |
| Chemical core scaffold |
Specific heterocyclic or aromatic core |
Similar scaffolds but with different substituents |
Broad composition claim |
| Substituents |
Specific functional groups at defined positions |
Variations known in prior art |
Claims narrow or broad depending on scope |
| Therapeutic application |
Treatment of a specific disease (e.g., neurodegeneration) |
Similar indications; patent claims are intended to cover these |
Defines patent's market focus |
| Formulation type |
Sustained-release, nanoparticle, etc. |
Known delivery mechanisms |
Protects specific delivery method |
6. Key Patent Landscape Considerations
-
Patent Strengths:
- Wide compound coverage via Markush structures.
- Method claims covering treatment indications.
- Formulation-specific claims.
-
Limitations:
- Potential prior art challenge if similar compounds disclosed before filing.
- Narrower claims may be vulnerable to invalidation or design-arounds.
-
Strategic Implications:
- Monitoring of patent expirations and freedom-to-operate assessments are vital.
- Licensing opportunities could be explored for formulation or use claims.
- Defensive patenting around alternative compounds or delivery systems.
7. Summary of Patent Landscape
Table 1: Key Patent Status and Strategies
| Aspect |
Details |
| Patent Family Size |
Multiple filings across jurisdictions; comprehensive protection strategy. |
| Main Competitors |
Several pharmaceutical and biotech firms with similar protected compounds or methods. |
| Potential Infringement Risks |
Companies developing similar compounds or formulations; need for clearance analyses post-2030 expiry. |
| Licensing Opportunities |
Use and formulation claims potential targets for licensing or collaboration. |
| Research Freedom |
Validity dependent on prior art; ongoing patent landscape monitoring crucial. |
8. Summary Table: Claims Breakdown
| Claim Category |
Number of Claims (Estimate) |
Scope |
Notes |
| Composition of matter |
10–15 |
Broad chemical structures with specific features. |
Core of patent protection. |
| Use claims for therapeutic methods |
8–12 |
Treatment of specific diseases. |
Extends protection to methods of use. |
| Delivery/formulation claims |
3–6 |
Specific formulations and delivery methods. |
Protects specific product configurations. |
| Processes for synthesis |
2–4 |
Manufacturing techniques. |
Complements composition claims. |
Key Takeaways
-
Scope: The '130 patent primarily protects a broad class of chemical compounds and their therapeutic use, including formulation-specific claims, providing extensive coverage within its filed claims.**
-
Claims Strategy: Broad composition claims, coupled with method of use, bolster the patent's defense against design-arounds; however, narrower claims might be susceptible to invalidation if prior art exists.
-
Patent Landscape: The patent's family and jurisdiction coverage suggest robust protection, yet competing patents and prior art require ongoing monitoring to maintain freedom to operate.
-
Market Implications: The end of patent life around 2030 opens opportunities for generics, but until then, licensing, partnership, and strategic IP management are key.
-
Validation and Challenges: The validity hinges on novelty and non-obviousness; proactive prior art searches and legal defenses are crucial.
FAQs
Q1: What is the primary therapeutic target covered by the '130 patent?
The patent appears to target neurological conditions such as neurodegenerative diseases, based on its claims for use.
Q2: How broad are the chemical claims of the patent?
The claims encompass a wide class of compounds with specific core structures and substituents, designed to cover variants and derivatives.
Q3: Can this patent be challenged based on prior art?
Yes, if prior disclosures or publications demonstrate similar compounds or methods, validity could be disputed.
Q4: Are there existing patents similar to the '130 patent?
Yes, related patents exist in family members and competitors' portfolios, covering similar chemical classes or therapeutic uses.
Q5: When does the patent expire, and what are the implications?
Expected expiry is September 2030, after which generic manufacturing and sales may proceed subject to licensing and legal considerations.
References
[1] United States Patent and Trademark Office. Patent No. 8,536,130. Issued September 17, 2013.
[2] WIPO Patent Scope. Patent Family Data.
[3] Relevant scientific literature and prior art disclosures cited during examination.
[4] Patent landscape reports from global patent analytics firms.
More… ↓
⤷ Start Trial
|
